Objectives: The aim of this study was to determine whether the acute inhibition of nitric oxide (NO) synthase causes changes in cardiac substrate utilization which can be reversed by a NO donor. Methods: NO synthase was blocked by giving 30 mg / kg of nitro-L-arginine (NLA) i.v. to 15 chronically instrumented dogs. Hemodynamics and blood samples from aorta and coronary sinus were taken at control and at 1 and 2 h after NLA. In five dogs, 0.4 mg / kg of the NO donor 3754 was given i.v. 1 h after NLA. In six dogs, angiotensin II was infused over 2 h (20-40 ng / kg / min) to mimic the hemodynamic effects of NLA. Results: Two h after NLA: mean arterial pressure was 15364 mmHg; MVO increased by 38%; cardiac uptake of lactate and glucose increased, respectively, from 2 20.065.0 to 41.069.3 mmol / min and from 1.160.7 to 6.861.5 mg / min (all P,0.05 vs. control). Cardiac uptake of free fatty acids decreased by 43% after 1 h (P,0.05) and returned to control values at 2 h. Cardiac respiratory quotient increased from 0.7660.03 to 1.0560.07, indicating a shift to carbohydrate oxidation. All these changes were reversed by the NO donor. In the dogs receiving angiotensin II infusion, MVO increased by 28% and lactate uptake doubled (both P,0.05), but no other metabolic changes where 2 observed. Conclusions: The acute inhibition of NO synthase by NLA causes a switch from fatty acids to lactate and glucose utilization by the heart which can be reversed by a NO donor, suggesting an important regulatory action of NO on cardiac metabolism.
Introduction
study from our laboratory has described an association between the fall in cardiac NO production and a switch in Over the last 10 years, several studies in vitro and in myocardial substrate uptake and oxidation during decomvivo have demonstrated or suggested that one of the pensation of pacing-induced heart failure [6] . In end stage functions of nitric oxide (NO) consists of the regulation of failure, the heart shifts from prevalent free fatty acids important metabolic pathways. NO modulates oxygen (FFA) to carbohydrate utilization. A similar switch in consumption by inhibiting the complexes I, II and IV of the uptake occurs also in normal animals after competitive mitochondrial electron transport chain [1] and the aconitblockade of NO synthase (NOS) by nitro-L-arginine (NLA) ase, although the effect of NO on this enzyme is still [6, 7] . Another recent study has shown that NO inhibits controversial [2] . Some studies indicate that NO facilitates myocardial glucose uptake, via cGMP, in vitro [8] , supglucose utilization, likely by potentiating the action of porting our previous findings in vivo. insulin [3] or stimulates total substrate oxidation, by On the basis of these studies, we have proposed a activating a cGMP-dependent protein kinase [4] . Others modulatory action of NO, tonically released by misuggest an opposite role, since NO inhibits GAPDH, a key crovascular endothelium, on myocardial oxygen consumpenzyme of the glycolytic pathway [5] . Finally, a recent tion [7] [8] [9] and metabolic pathways. In fact, a much higher concentration of constitutive NOS is present in endothelial cells compared to cardiomyocytes [10] . Hypothetically, an impaired endothelial production of nitric oxide, as may surgery and the dogs were allowed to fully recover. After occur in atherosclerosis, hypertension, cardiac ischemia 10 days, dogs were trained to lie quietly on the laboratory and heart failure [6, [11] [12] [13] [14] , could affect myocardial me- [15] [16] [17] .
2.2. Hemodynamic recordings These intermediates can alter the biophysical equilibrium in myocytes and contribute to the development of cardiac
The aortic catheter was attached to a P23ID strain-gauge arrhythmias [15] . Moreover, since the early 60s it has been transducer for measurement of aortic pressure. LV pressure shown that glucose rather than FFA oxidation improves was measured using the solid-state pressure gauge. The recovery from acute myocardial infarction [18] . If NO first derivative of LV pressure, LV dP/dt, was obtained really plays a key role in the regulation of myocardial using an operational amplifier (National Semiconductor substrate utilization, it follows that nitrovasodilators, NO-LM 324), and triangular wave signals with known slope releasing agents traditionally employed in the treatment of were substituted for the pressure signals to calibrate the heart failure and myocardial ischemia, may be beneficial differentiator directly. Coronary blood flow was measured by directly modulating cardiac oxygen consumption and with a pulsed Doppler flowmeter (Model 100, Triton). This substrate utilization. The aims of the present investigation technique has been used in our previous studies [6, 7, 19] . were to determine if : (1) acute inhibition of NOS can All signals were recorded on a 14-channel tape recorder result in altered substrate utilization by the heart and (2) (Bell and Howell 3700B) and played back on an eightthis can be reversed by acute administration of a NO channel direct-writing oscillograph (Gould RS 3800). donor. The efficacy of the NO donor would confirm that Mean values of aortic pressure and coronary flow were cardiac metabolic changes observed after inhibition of obtained by filtering the respective signals at 2 Hz. Heart NOS are effectively due to the lack of NO and could rate was measured using a cardiotachometer (model provide new insights into the therapeutic action of nitro-9857B, Beckman) from the LV pressure pulse interval. For vasodilators in the treatment of chronic heart failure and some data analysis, the tape was played back and the cardiac ischemia.
analog signals stored in computer memory through an analog-digital interface (National Instruments), at a sampling rate of 250 Hz.
Methods
Mean coronary resistance was obtained by dividing mean aortic pressure by mean coronary flow (mmHg?min / 2.1. Surgical procedure and instrumentation ml).
Male dogs (n521) weighing 25-27 kg were sedated 2.3. Cardiac metabolites and insulin with acepromazine maleate (1 mg / kg, i.m.), anesthetized with sodium pentobarbital (25 mg / kg, i.v.) and ventilated Blood samples from aorta and coronary sinus were with room air. A thoracotomy was performed in the left collected into plastic syringes treated either with heparin or fifth intercostal space. Catheters (Tygon) were placed in EDTA and immediately stored on ice. Special care was the descending thoracic aorta and left atrial appendage for taken to withdraw blood slowly from the coronary sinus pressure measurements. A third catheter was inserted in the catheter to avoid potential contamination of the sample coronary sinus by perforating its wall. The length of the with right atrial blood. Blood gases were measured in a inserted segment was such that the tip of the catheter led blood gas analyzer (Corning, model 170). PO was 2 away from the right atrium. During surgery, a blood multiplied by 0.003 to obtain the concentration of oxygen sample was taken from the catheter and immediately dissolved in plasma [20] and added to oxygen concenmeasured on a pH / blood gas analyzer. If the PO was . 25 tration measured by an hemoglobin analyzer (CO-Oxime-2 mmHg, the catheter was repositioned and finally tied into ter, Instruments Laboratory) to obtain total oxygen content place. A solid-state pressure gauge (P6.5, Konigsberg) was in whole blood (v / v). Hematocrits were measured after inserted in the left ventricle (LV) through the apex. A centrifugation. Lactate was measured from whole blood Doppler flow probe (Parks Electronics) was placed around using a lactate analyzer (YSI 1500 Sport, Yellow Springs the left circumflex coronary artery. A human, screw-type, Instrument). Glucose and FFA concentrations were deunipolar myocardial pacing lead was placed on the LV. termined in plasma after centrifugation of the blood Wires and catheters were run subcutaneously to the samples at 1000 g for 15 min at 08C. Glucose was intrascapular region, the chest was closed in layers and the measured using a glucose analyzer (Beckman Glucose 2, pneumothorax was reduced. Antibiotics were given after Beckman). FFA analysis was performed on plasma from EDTA treated samples using a colorimetric assay (NEFA sinus blood samples were taken at control from all 21 dogs C kit from Wako). The arterial-coronary sinus concenplaced on the laboratory table. The heart was paced at tration difference (A2CS) of oxygen, lactate, glucose and 13261 beats / min in order to maintain the same heart rate FFA contents was multiplied by mean coronary blood at control and during the protocols. Two groups of dogs flow, assumed as double of mean flow measured in the left were used, one group to test the effects of NOS blockade circumflex coronary artery [21] to calculate cardiac conon cardiac metabolism and the second group to test the sumption. We have described these methods previously effects of angiotensin II, a vasopressor which is not a NOS [6, 7] .
inhibitor. In the first group of dogs (n515) a dose of 30 Insulin concentration in arterial plasma was measured mg / kg of NLA (Aldrich), a specific NOS inhibitor, was 125 using a solid-phase I radioimmunoassay (Coat-A-Count given intravenously in bolus. We previously found that this 125 Insulin, Diagnostic Products). In this assay, I-labeled dose reduces the vasodilation to acetylcholine by .60% in insulin competed for a fixed time with insulin contained in conscious dogs and abolishes the basal release of NO plasma samples for sites on insulin-specific antibody metabolites by the heart [7, 19] . The same dose inhibits immobilized to the wall of a polypropylene tube. After systemic NO synthesis by 90% in rats [26] . Hemodynamic decanting the supernatant, residual radioactive activity was changes were recorded during the following hour. Blood counted in a gamma counter (Searle 8500).
samples were taken 60 min after NLA injection and two different protocols were followed, in two subsets of dogs, during the second hour post-NLA. In ten dogs blood 2.4. Cardiac production of CO and respiratory quotient 2 samples were drawn 120 min after NLA. In five dogs, 0.4 (RQ) mg / kg of 3754, the active metabolite of the long acting NO donor Pirsidomine (Hoechst-Roussel) [27] , was adSince the metabolic fate of substrates was not measured ministered intravenously in bolus 1 h after NLA. Blood in this study, cardiac RQ was used as an index of substrate samples were taken 5, 15, 30 and 60 min after administraoxidation. RQ is calculated from the measured oxygen tion of 3754. consumption and CO production by the heart. It is given infused over 2 h at the dose of 20-40 ng / kg / min. The between 0.707, corresponding to oxidation of FFA as the infusion rate was adjusted to obtain the same values of only substrate, and 1, corresponding to oxidation of mean arterial pressure measured in dogs receiving NLA carbohydrates as the only substrate [22] . Classical studies and also the heart was paced at the same rate of 13261 on cardiac metabolism have utilized this index to indirectly beats / min. Hemodynamic changes were recorded during determine the type of substrate oxidized by the heart the 2 h of infusion and blood samples were taken at 1 and [23, 24] . Cardiac RQ was calculated as described previous-2 h. ly [6] . Briefly, we calculated total cardiac CO concen-2 tration either in arterial and coronary sinus blood as 2.6. Statistical analysis described by Davenport [25] : given by (produced CO ) / MVO , which can be simplified NLA1NO donor (3754) are displayed in Fig. 1 receiving NLA alone or NLA1 NO donor, are shown in Fig. 2 . All changed significantly after NLA and the changes were reversed by the NO donor. FFA uptake decreased significantly 1 h after NLA, but returned to control values after 2 h. The action of the NO donor on cardiac metabolism occurred within 5 min after administration, as shown in Fig. 2 . Changes in the concentration of cardiac substrates in arterial plasma are listed in Table 1 . Arterial FFA decreased significantly from control 1 h after NLA and was still lower after 2 h. This decrease was rapidly reversed by the NO donor. Arterial plasma glucose and lactate concentrations did not change significantly. Fig.  3 shows the changes of insulin concentration in arterial plasma after NLA and NLA 1NO donor. Insulin concentration decreased by 50% at 1 and 2 h after NLA and this change was partially reversed by the NO donor. The changes in MVO and uptake of FFA, glucose and 2 lactate, together with the changes in arterial concentration of these substrates, during angiotensin infusion, are listed in Table 2 . FFA and glucose uptake did not change whereas lactate uptake doubled. during infusion of angiotensin II are reported in Table 2 . dP/dt decreased from 2709657 mmHg / s to 22206117 max There was no significant change over time. and 22616112 mmHg / s at 1 and 2 h after NLA, respectively (P,0.05). One h after 3754, dP/dt was further max decreased to 18006120 mmHg / s. This was most likely due to reduced preload by the NO donor. Mean coronary 4. Discussion vascular resistance was 3.560.2 mmHg?min / ml and did not change significantly after NLA or NLA1NO donor
The present study demonstrates that acute inhibition of (3754).
NO production causes a reduction of myocardial utilization Angiotensin infusion caused the following increases in of FFA and an increase in carbohydrate (lactate1glucose) hemodynamic values: mean arterial pressure from 10565 utilization. The metabolic changes can be rapidly reversed mmHg at control to 15162 and 15665 mmHg at 1 and 2 by a NO donor. In particular, the increase in lactate uptake h, respectively (P,0.05); LVSP from 12066 mmHg at is likely driven by the elevated ventricular afterload, since control to 16963 and 17064 mmHg at 1 and 2 h (P, it occurs also in the control group receiving angiotensin II. 0.05). dP/dt from 2537678 mmHg / s at control to On the other hand, the increase in glucose uptake and in max 2825668 and 28866112 mmHg / s at 1 and 2 h, respeccardiac RQ are present only when NOS is blocked and are tively (P,0.05); mean coronary flow in the left circumflex not insulin-dependent. These findings strongly suggest that coronary from 34.062.4 ml / min at control to 37. 063.3 NO is involved in regulation of cardiac substrate utilization and 39.063.7 ml / min at 1 and 2 h, respectively (nonsigand reveal a potential novel pharmacological action of nificant); mean coronary resistance increased from nitrovasodilators in conditions of reduced synthesis of NO. 3.160.2 mmHg?min / ml to 4.260.3 and 4.260.5 mmHg?
The effects of the NO donor on cardiac metabolism could min / ml, respectively (P,0.05).
be potentiated by the supersensitivity of the soluble guanylate cyclase to exogenous NO, which occurs after after administration of NLA [6, 7] . The present study NOS blockade, as shown in vitro and in vivo [28] . In a provides a further basis to the previous results. previous study [6], we have described an association To date, the role of NO in the regulation of cardiac between the fall in cardiac NO production and the switch substrate utilization is almost unexplored. A recent study in substrate utilization in end stage heart failure. The in isolated hearts has shown that cGMP, a second mesinvolvement of NO in this metabolic alteration was senger of NO, inhibits cardiac glucose utilization and suggested by similar changes in cardiac uptake observed stimulates the synthesis of malonyl-CoA, an inhibitor of arginine analogue NLA [30] . Yet, our data indicate that long-chain FFA oxidation [8] . However, the heart was insulin concentration fell by 50% after NLA, confirming perfused with Krebs-Henseleit buffer containing glucose previous reports of the inhibitory action of NOS blockade as the only substrate. Interestingly, our results indicate a on the endocrine pancreas [31] . 3754 was able to raise similar inhibition by NO on glucose, but not on FFA, insulin levels, although not completely. Another possible utilization. It is likely that the NO-mediated control on cause of altered cardiac metabolism occurring after NLA cardiac metabolism is in part different in vivo, where all or NO donor could be the changes in neurovegetative the substrates are supplied and the oxygen delivery to the activity. In our experiments, we did not measure sympaheart is optimal. Cardiac muscle utilizes primarily FFA in thetic activity, but previous findings in conscious rabbits fasting state [23, 24, 29] . In dogs, we found a baseline demonstrated that NOS blockade causes a reduction in cardiac RQ of 0.755, indicating that more than 80% of the sympathetic outflow [32] mainly due to the baroreflex oxidized substrates were FFA.
response triggered by high blood pressure. However the Factors other than NOS inhibition that could have baroreflex response was triggered also during angiotensin caused profound alterations in cardiac metabolism in our infusion, when only minimal changes in cardiac metaboexperiments were the hemodynamic, hormonal, and neurolism were found. Moreover, studies in vitro clearly indicate humoral changes. However, we can exclude that the that NO / cGMP provides a direct control of glucose marked elevation in blood pressure, after NLA, determined utilization [5, 8] . Despite these considerations, we cannot a switch in substrate utilization. During infusion of anexclude a role played by the neurovegetative changes. giotensin II, MVO increased by 25-28% and only lactate Finally, an important factor that strongly influences cardiac 2 uptake increased twofold, whereas glucose and FFA substrate utilization is metabolite concentration in arterial uptake and RQ remained unchanged. These results indicate blood [17] . In particular, the human heart preferentially that the ventricular pressure development stimulates lactate utilizes carbohydrates when arterial FFA concentration uptake, yet the oxidation of FFA remains prevalent. Insulin falls below the threshold of 0.3 mequiv / l [17] . The arterial stimulates cardiac glucose uptake and oxidation [17] . The plasma concentration of lactate and glucose did not change observed switch in cardiac substrate consumption and the significantly after NLA, whereas FFA concentration fell fall in FFA concentration could be indeed due to the below the threshold at 1 h after NLA, likely causing the release of insulin triggered in pancreatic beta-cells by the reduction in uptake of FFA at that time point. Two h after NLA, FFA uptake returned to control levels and RQ doses of NLA lower than 30 mg / kg could determine reached 1, indicating prevalent carbohydrate oxidation.
hemodynamic changes with no metabolic effects or vice Therefore, the changes in FFA utilization after NLA can be versa. Finally, the calculation of RQ was based on CO 2 divided in two components: uptake and oxidation. Uptake content in whole blood, which was calculated using returned to normal values after 2 h, when the arterial FFA measures of pH, pCO , hematocrit, total and reduced 2 concentration exceeded the threshold of 0.3 mequiv / l. The hemoglobin. However, partial values of RQ, which inimpairment of fat oxidation was not FFA concentrationcluded only the CO directly measured in plasma by the 2 dependent and was complete 2 h after NLA. To our blood gas analyzer, still increased significantly after NLA, knowledge, this is the first study describing a control by indicating that the calculation of total CO did not generate 2 NO on cardiac FFA oxidation in vivo. On the basis of the misleading artefacts (data not shown). present data, it is not possible to define the mechanism of In summary, this study suggests a control by NO on control, nor the fate of the nonoxidized FFA, which were cardiac substrate utilization. We hypothesize that endogenprobably accumulated as FFA and / or as metabolic interous NO released in the heart functions as a paracrine factor mediates or were incorporated in the myocardial pool of that promotes FFA oxidation and inhibits carbohydrates triacylglycerols. However, the regulatory role of NO was oxidation. The main source of NO is likely the miconfirmed by the action of 3754, which rapidly reversed crovascular endothelium, which contains a much higher these metabolic alterations.
concentration of NOS compared to cardiomyocytes Some interesting analogies can be proposed between [10, 42] , although an important role of NOS activity in myocardial metabolic changes due to competitive inhibicardiomyocytes [10, 43] , cannot be excluded. The loss of tion of NOS and metabolic abnormalities associated with NO, due to competitive inhibition of NOS, causes a switch cardiac diseases. For example, impaired release of NO from prevalent FFA to carbohydrate oxidation. This metafrom endothelial cells has been found in chronic heart bolic alteration is insulin-independent and can be rapidly failure [14, 33] , which is also characterized by a switch reversed by exogenous NO, suggesting a novel pharmacofrom FFA to carbohydrate utilization in the heart [6, 34, 35] .
logical action of nitrovasodilators as regulators of myocar-A clinical investigation on failing hearts documented an dial metabolism in conditions of reduced availability of accumulation of long chain acyl-carnitine, an intermediate endogenous NO. of FFA metabolism, in cardiac tissue [16] . Accumulation of FFA, acyl-CoA and acyl-carnitine also represents a characteristic event in ischemic and postischemic myocarAcknowledgements dium [15] , when endothelial NOS activity is blunted [13] , but does not occur after ischemic preconditioning [36] , Supported by PO-1 HL43023, RO-1HL 50142 and HL when endothelial NO production is typically enhanced 53053 from the National Heart, Lung and Blood Institute. (1996) (1997) . oxidation observed during the postreperfusion period, but not after preconditioning, can be at least partially explained by the present data. On the other hand, prevalent glucose utilization could be advantageous, since less References oxygen is required to obtain the same amount of ATP from carbohydrates [39] . The oxygen saving due to switch in utilization did not occur. consumption, yet they represent a small percentage of total cardiac metabolism to NLA, so we cannot exclude that 
